This company listing is no longer active
MRV Stock Overview
Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Nuvo Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.35 |
| 52 Week High | CA$1.55 |
| 52 Week Low | CA$0.50 |
| Beta | 0.78 |
| 11 Month Change | 3.05% |
| 3 Month Change | 104.55% |
| 1 Year Change | -8.78% |
| 33 Year Change | 136.84% |
| 5 Year Change | -58.46% |
| Change since IPO | -99.48% |
Recent News & Updates
Recent updates
Nuvo Pharmaceuticals (TSE:MRV) Has A Somewhat Strained Balance Sheet
Aug 17
Is Nuvo Pharmaceuticals (TSE:MRV) Using Too Much Debt?
Sep 01Nuvo Pharmaceuticals Inc.'s (TSE:MRV) CEO Might Not Expect Shareholders To Be So Generous This Year
May 11These 4 Measures Indicate That Nuvo Pharmaceuticals (TSE:MRV) Is Using Debt Extensively
Feb 22Shareholder Returns
| MRV | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 0.7% | 1.2% | -0.7% |
| 1Y | -8.8% | -18.7% | 20.2% |
Return vs Industry: MRV exceeded the Canadian Pharmaceuticals industry which returned -62.1% over the past year.
Return vs Market: MRV exceeded the Canadian Market which returned -11.7% over the past year.
Price Volatility
| MRV volatility | |
|---|---|
| MRV Average Weekly Movement | 26.8% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.5% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: MRV's share price has been volatile over the past 3 months.
Volatility Over Time: MRV's weekly volatility has increased from 21% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 101 | Jesse Ledger | www.miravohealthcare.com |
Nuvo Pharmaceuticals Inc., doing business as Miravo Healthcare, provides prescription and non-prescription products for pain, allergy, neurology, and dermatology worldwide. The company operates in three segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. It offers Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticaria; Cambia, a nonsteroidal anti-inflammatory drug for migraine; Suvexx/Treximet, a migraine medicine; NeoVisc, an injectable viscosupplement for osteoarthritis; and Resultz, FullMarks, and LAUSBUB for head lice infestations.
Nuvo Pharmaceuticals Inc. Fundamentals Summary
| MRV fundamental statistics | |
|---|---|
| Market cap | CA$15.37m |
| Earnings (TTM) | CA$15.17m |
| Revenue (TTM) | CA$72.42m |
1.0x
P/E Ratio0.2x
P/S RatioIs MRV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRV income statement (TTM) | |
|---|---|
| Revenue | CA$72.42m |
| Cost of Revenue | CA$27.36m |
| Gross Profit | CA$45.06m |
| Other Expenses | CA$29.89m |
| Earnings | CA$15.17m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.33 |
| Gross Margin | 62.22% |
| Net Profit Margin | 20.95% |
| Debt/Equity Ratio | 1,149.7% |
How did MRV perform over the long term?
See historical performance and comparison